Abstract
Background and Purpose Spontaneous carotid artery dissections (sCAD) are the main cause of stroke in middle-aged and young people. There is still a lack of clinical classification to guide the management of sCAD. We reviewed our experience with 179 sCAD patients and proposed a new classification for sCAD with prognostic and therapeutic significance.
Methods This is a retrospective review of prospectively collected data from June 2018 to June 2023 of sCAD patients treated at a large tertiary academic institution in an urban city in China. Depending on the degree of luminal narrowing and pseudoaneurysm formation on imaging, sCAD was classified into four types. Type IV dissections were divided into type IVA and type IVB dissections according to the presence of intracranial occlusion.
Results A total of 179 patients and 197 dissected arteries met the inclusion criteria. More than two-thirds of type I dissections are completely recanalized after antithrombotic therapy, and only one case (1.8%) had recurrent ischemic stroke. A total of 38 % of type II dissections and 73% of type III dissections received endovascular treatment (EVT) for persistent flow-limited dissections, enlargement of pseudoaneurysm, or aggravation of clinical symptoms despite antithrombotic therapy. Type IV dissections are more likely to lead to the occurrence of ischemic stroke, and presented with more severe symptoms. About 33% of type IVB dissections received emergent intervention due to intracranial occlusion or aggravation of symptoms after medical treatment.
Conclusions This study proposes a novel and more comprehensive classification method and management strategy for sCAD. Antithrombotic therapy is beneficial to reduce the risk of recurrent stroke for stable sCAD like type I. Non-emergent EVT can be an alternative therapeutic approach for patients who meet indications as in type II to IVA. Urgent procedure with neurovascular intervention might be needed in those with type IVB SCAD. The short-term results of EVT for sCAD are encouraging, and long-term device-related and functional outcome should be elucidated.
- Carotid artery
- dissection
- Ischemic stroke
- Stenting
- Endovascular treatment
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project was partly supported by the Key Scientific Research Project of colleges and universities in Henan Province (22A320081)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
the ethical committee and Institutional Review Board of the First Affiliated Hospital of Zhengzhou University (Henan, China) Approval number:2022-KY-1452-001
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets used or analysed during the current study are available from the corresponding author on reasonable request.
